InteliSwab COVID-19 Rapid Test (2 Test/Box)
PRODUCT TYPE: At Home Testing
MANUFACTURER: Orasure
ATTENTION! Your health insurance may provide coverage for this product. Please check THIS listing and find out if your insurance will reimburse you! If you have specific insurance questions, submit a request for additional information by emailing PayerRelations@prism-medical.com
IMPORTANT! Please read the COVID-19 Test Kit Notice carefully. (The notice will open as a PDF file.) If you agree to the terms and conditions in the COVID-19 Test Kit Notice, click "I Agree" to enable the "Add to Cart" button.I agree
Meet InteliSwab, the COVID-19 rapid antigen test that makes self-testing remarkably simple. It’s so user-friendly, it can be used anytime and anywhere, and requires less than one minute of hands-on time. InteliSwab has received FDA Emergency Use Authorization* for self-testing. You do not need to ship samples to a lab or get a prescription from your healthcare provider. Use requires just 3 key steps: Swab, Swirl and See your result in 30 minutes. There is no assembly required. InteliSwab makes testing so easy, you’ll know you did it right.
- Detects active COVID-19 infection for both symptomatic and asymptomatic use
- Shallow and gentle nasal swab (lower nostril)
- 98% of untrained, unproctored users found InteliSwab™ easy to use
- Requires less than one minute of hands-on time
- No lab needed and no assembly required
- Get your results in 30 minutes
- No difficult or confusing steps
- No dropper bottle or number of drops required
- No batteries or instruments needed
- Designed in Bethlehem, Pennsylvania by OraSure Technologies, Inc.
- Suitable for ages 15 and up
- Bilingual instructions included
*This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA; This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens; and, This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.